Genmab has signed an agreement with Janssen Biotech, Inc. to collaborate exclusively on a next-generation CD38 antibody product, HexaBody^®-CD38, incorporating Genmab’s HexaBody technology. The new agreement builds on Genmab’s successful DARZALEX^® collaboration with Janssen. HexaBody-CD38 could potentially add to the DARZALEX multiple myeloma franchise and expand the potential of CD38-targeted therapies in further indications. For HexaBody-CD38, Genmab obtained promising pre-clinical data in a panel of multiple myeloma, lymphoma and leukemia models. 

“With this agreement, we hope to build upon the successful and productive relationship that we have established with Janssen. As a result of our collaboration, DARZALEX has dramatically improved outcomes for patients with multiple myeloma, yet there are still unmet needs for patients. We are excited that Genmab’s world-class antibody expertise and passion for innovation has led to the novel HexaBody-CD38 product concept. Encouraging pre-clinical data suggest that HexaBody-CD38 could be superior to daratumumab for certain tumor cell types and may expand and extend the promise of CD38-targeted therapies for more patients with multiple myeloma, lymphoma, leukemia, and potentially beyond,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.